Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

News:Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia

• Share

• (opens new window)

• (opens new window)

• (opens new window)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc.(Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that management will present at the Stifel 2026 Virtual Cardiometabolic Forum. The fireside chat will take place on Wednesday, September 30th, 2026, at 9:30 a.m. ET.

A live webcast of the presentation can be accessed under “Events and Presentations” in the Investor section of the Company’s website,https://investors.amylyx.com/events-presentations, and will be available for replay for 90 days following the events.

At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on four investigational therapies across several endocrine conditions and neurodegenerative diseases in which we believe they can make the greatest impact. For more information, visitamylyx.comand follow us onLinkedInandX. For investors, please visitinvestors.amylyx.com.

Get the latest news and updates from Amylyx, delivered right to your inbox.

For investors, please clickherefor email alerts.

Thank you for subscribing to our news and updates and connecting with us. It’s connections like these that propel us forward in pursuit of what’s next.

Please add us to your safe sender’s list.

Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia